BERLIN (Reuters) -German pharma company Bayer reported positive study results for its anticoagulant asundexian on Sunday, two years after a research setback for the promising blood thinner candidate.
In a Phase III study, a daily dose of 50 milligrams significantly reduced the risk of ischemic stroke compared with a placebo, Bayer said.
Detailed results from the OCEANIC-STROKE study will be presented at an upcoming scientific congress, said Bayer.
Bayer added that it plans to speak with health authorities worldwide in preparation for the submission of marketing authorisation applications.
Bayer had originally predicted that asundexian would have peak sales potential of more than 5 billion euros ($5.76 billion) - more than any of its other drugs.
At the end of 2023, the company had a major setback with the drug after it failed in a pivotal clinical trial involving patients with atrial fibrillation and a risk of stroke.
($1 = 0.8687 euros)
(Reporting by Joern Poltz. Writing by Miranda Murray. Editing by Jane Merriman)
LATEST POSTS
- 1
Style Narratives: A Survey of \Patterns and Styles Assessed\ Design - 2An 'explosion' of solo-agers are struggling with rising costs and little support: 'I'm flying without a net'
- 3Benin coup thwarted by loyalist troops, president tells nation
- 4Cannabis reclassification could 'open the floodgates' for research, scientists say
- 5Ukrainian Army Converts E38 BMW 7-Series Into Multiple Rocket Launch Platform
- Understanding Various Sorts of Financial balances: An Extensive Outline
- 5 Must-Attempt Fascinating Dishes from Around the World
- Israel violated ceasefire with Hezbollah more than 10,000 times, UNIFIL claims
- Which '80s Film Actually Holds Up Today?
- Famous SUVs With Low Energy Utilization In 2024
- Instructions to Decide the Best SUV Size for Seniors
- PA accuses Israel of 'human trafficking' after planeload of Gazans arrives in South Africa
- AbbVie plans to build out its presence in obesity market
- Cuba fights to contain spread of mosquito-borne chikungunya virus
